- Approval Id
- 252dc24eb0c952bc
- Drug Approval Emc Name
- Xaggitin XL 18mg Prolonged-release Tablets
- Drug Name
- Xaggitin XL 18mg Prolonged-release Tablets
- Company Name
- Martindale Pharma, an Ethypharm Group Company
- Company Address
- Jupiter House, Mercury Park, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, UK
- Company Website
- http://ethypharm.co.uk/
- Company Telephone
- +44 (0) 1277 266 600
- Company Medical Info Email
- medinfo@ethypharm.com
- Atc Code
- N06BA04
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Macarthys Laboratories Ltd T/A Martindale Pharma
Bampton Road Harold Hill, Romford, Essex
RM38UG
United Kingdom
- Authorisation Number
- PL 01883/0359
PL 01883/0360
PL 01883/0361
PL 01883/0362
- Authorisation Date
- 14/07/2016
- Instruction Authorisation Holder
- Macarthys Laboratories Ltd T/A Martindale Pharma
Bampton Road Harold Hill, Romford, Essex
RM38UG
United Kingdom
- Instruction Authorisation Number
- PL 01883/0359
PL 01883/0360
PL 01883/0361
PL 01883/0362
- Instruction Authorisation Date
- 14/07/2016
- Instruction Dosage Form
- Prolonged-release tablet.
18 mg Tablet: Capsule-shaped, biconvex, yellow tablet, 6.6 mm x 11.9 mm, with “2392” printed on one side in black ink.
27 mg Tablet: Capsule-shaped, biconvex, grey tablet, 6.7 mm x 12.0 mm, with “2393” printed on one side in black ink.
36 mg Tablet: Capsule-shaped, biconvex, white tablet, 6.7 mm x 12.0 mm, with “2394” printed on one side in black ink.
54 mg Tablet: Capsule-shaped, biconvex, red-brown tablet, 6.8 mm x 12.0 mm, with “2395” printed on one side in black ink
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
\*\*Attention-Deficit/Hyperactivity Disorder (ADHD)\*\*
Xaggitin XL is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over and adults when remedial measures alone prove insufficient. Treatment must be initiated and supervised by a physician specialised in the treatment of ADHD such as an expert paediatrician, a child and adolescent psychiatrist or an adult psychiatrist.
Special Diagnostic Considerations for ADHD in children
Diagnosis should be made according to the current DSM criteria or ICD guidelines and should be based on a complete history and evaluation of the patient. Third-party corroboration is desirable and diagnosis cannot be made solely on the presence of one or more symptom.
The specific aetiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and specialised psychological, educational, and social resources.
A comprehensive treatment programme typically includes psychological, educational and social measures as well as pharmacotherapy and is aimed at stabilising children with a behavioural syndrome characterised by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impaired.
Methylphenidate treatment is not indicated in all children with ADHD and the decision to use the medicinal product must be based on a very thorough assessment of the severity and chronicity of the child's symptoms in relation to the child's age.
Appropriate educational placement is essential, and psychosocial intervention is generally necessary. Where remedial measures alone prove insufficient, the decision to prescribe a stimulant must be based on rigorous assessment of the severity of the child's symptoms. The use of methylphenidate should always be used in this way according to the licensed indication and according to prescribing/diagnostic guidelines.
Special Diagnostic Considerations for ADHD in adults
Diagnosis should be made according to the current DSM criteria or ICD guidelines, and should be based on a complete history and evaluation of the patient.
The specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adults with ADHD have symptom patterns characterised by restlessness, impatience, and inattentiveness. Symptoms such as hyperactivity tend to diminish with increasing age, possibly due to adaptation, neurodevelopment and self-medication. Inattentive symptoms are more prominent and have a greater impact on adults with ADHD. Diagnosis in adults should include a structured patient interview to determine current symptoms. The pre-existence of childhood ADHD is required and has to be determined retrospectively (by patient's records or, if not available, by appropriate and structured instruments/interviews). Third-party corroboration is desirable and treatment should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis should not be made solely on the presence of one or more symptoms. The decision to use a stimulant in adults must be based on a very thorough assessment and diagnosis should include moderate or severe functional impairment in at least 2 settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual's life.4.2 Posology and method of administration
Treatment must be initiated and supervised by a physician specialised in the treatment of ADHD such as an expert paediatrician, a child and adolescent psychiatrist or an adult psychiatrist.
\*\*Pre-treatment screening\*\*
In adults new to Xaggitin XL, and if required by national practice, cardiologist advice is needed prior to treatment initiation in order to check the absence of cardiovascular contraindications.
Prior to prescribing, it is necessary to conduct a baseline evaluation of a patient's cardiovascular status including blood pressure and heart rate. A comprehensive history should document concomitant medications, past and present co-morbid medical and psychiatric disorders or symptoms, family history of sudden cardiac/unexplained death and accurate recording of pre-treatment height and weight on a growth chart (see sections 4.3 and 4.4).
\*\*Ongoing monitoring\*\*
Growth, psychiatric and cardiovascular status should be continuously monitored (see also section 4.4).
• Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months;
• Height, weight and appetite in children should be recorded at least 6 monthly with maintenance of a growth chart;
• Weight should be recorded for adults regularly;
• Development of de novo or worsening of pre-existing psychiatric disorders should be monitored at every adjustment of dose and then at least every 6 months and at every visit.
Patients should be monitored for the risk of diversion, misuse and abuse of methylphenidate.
\*Dose titration\*
Careful dose titration is necessary at the start of treatment with methylphenidate. Dose titration should be started at the lowest possible dose. A 27 mg dosage strength is available for those who wish to prescribe between the 18 mg and 36 mg dosages.
For doses not realisable/practicable with this medicinal product, other strengths and medicinal products are available.
Dosage may be adjusted in 18 mg increments. In general, dosage adjustment may proceed at approximately weekly intervals.
\*Children\*
The maximum daily dosage is 54 mg.
\*Adults\*
The maximum daily dosage is 72 mg.
\*\*Posology\*\*
\*Children/ adults new to methylphenidate\*
Xaggitin XL may not be indicated in all children/adults with ADHD syndrome. Lower doses of short-acting methylphenidate formulations may be considered sufficient to treat children/adults new to methylphenidate. Careful dose titration by the physician in charge is required in order to avoid unnecessarily high doses of methylphenidate. The recommended starting dose of Xaggitin XL for children/adults who are not currently taking methylphenidate, or for children/adults who are on stimulants other than methylphenidate, is 18 mg once daily.
\*Patients currently using methylphenidate\*
The recommended dose of Xaggitin XL for patients who are currently taking methylphenidate three times daily at doses of 15 to 60 mg/day is provided in Table 1. Dosing recommendations are based on current dose regimen and clinical judgement.
TABLE 1
Recommended dose conversion from other methylphenidate hydrochloride regimens, where available, to Xaggitin XL
| | |
| --- | --- |
| Previous methylphenidate hydrochloride daily dose | Recommended Xaggitin XL dose |
| 5 mg three times daily | 18 mg once daily |
| 10 mg three times daily | 36 mg once daily |
| 15 mg three times daily | 54 mg once daily |
| 20 mg three times daily | 72 mg once daily |
If improvement is not observed after appropriate dosage adjustment over a one-month period, the medicinal product should be discontinued.
\*\*Long-term (more than 12 months) use\*\*
The safety and efficacy of long-term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. In children and adolescents, methylphenidate treatment is usually discontinued during or after puberty. The physician who elects to use methylphenidate for extended periods (over 12 months) in patients with ADHD should periodically re-evaluate the long-term usefulness of the medicinal product for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy.
It is recommended that methylphenidate is de-challenged at least once yearly to assess the patient's condition (for children, preferably during times of school holidays). Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued.
\*\*Dose reduction and discontinuation\*\*
Treatment must be stopped if the symptoms do not improve after appropriate dosage adjustment over a one-month period. If paradoxical aggravation of symptoms or other serious adverse events occur, the dosage should be reduced or discontinued.
\*\*Special populations\*\*
\*Elderly\*
Methylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group. Methylphenidate has not been studied in ADHD in patients older than 65 years.
\*Hepatic or renal impairment\*
Methylphenidate has not been studied in patients with hepatic or renal impairment.
\*Children under 6 years of age\*
Methylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.
\*\*Method of administration\*\*
Xaggitin XL is for oral use once daily in the morning.
Xaggitin XL may be administered with or without food (see section 5.2).
The prolonged-release tablets must be swallowed whole with the aid of liquids, and must not be chewed, broken divided, or crushed (see section 4.4).4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Glaucoma
• Phaeochromocytoma
• During treatment with non-selective, irreversible monoamine oxidase (MAO) inhibitors, or within a minimum of 14 days of discontinuing those medicinal products, due to the risk of hypertensive crisis (see section 4.5)
• Hyperthyroidism or thyrotoxicosis
• Diagnosis or history of severe depression, anorexia nervosa/anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic/borderline personality disorder
• Diagnosis or history of severe and episodic (Type I) Bipolar (affective) Disorder (that is not well-controlled)
• Pre-existing cardiovascular disorders including severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life- threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels)
• Pre-existing cerebrovascular disorders cerebral aneurysm, vascular abnormalities including vasculitis or stroke4.4 Special warnings and precautions for use
Methylphenidate treatment is not indicated in all patients with ADHD and the decision to use the medicinal product must be based on a very thorough assessment of the severity and chronicity of the patient's symptoms. When treatment of children is considered, assessment of the severity and chronicity of the child's symptoms should be related to the child's age (6-18 years).
\*\*Long-term use (more than 12 months)\*\*
The safety and efficacy of long-term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. In children and adolescents, methylphenidate treatment is usually discontinued during or after puberty. Patients on long-term therapy (i.e. over 12 months) must have careful ongoing monitoring according to the guidance in sections 4.2 and 4.4 for cardiovascular status, growth (children), weight, appetite, development of de novo or worsening of pre-existing psychiatric disorders. Psychiatric disorders to monitor for are described below, and include (but are not limited to) motor or vocal tics, aggressive or hostile behaviour, agitation, anxiety, depression, psychosis, mania, delusions, irritability, lack of spontaneity, withdrawal and excessive perseveration.
The physician who elects to use methylphenidate for extended periods (over 12 months) should periodically re-evaluate the long-term usefulness of the medicinal product for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the patient's condition (for children, preferably during times of school holidays). Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued.
\*\*Use in the elderly\*\*
Methylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group. Methylphenidate has not been studied in ADHD in patients older than 65 years.
\*\*Use in children under 6 years of age\*\*
Methylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.
\*\*Cardiovascular status\*\*
Patients who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden cardiac or unexplained death or malignant arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further specialist cardiac evaluation if initial findings suggest such history or disease. Patients who develop symptoms such as palpitations, exertional chest pain, unexplained syncope, dyspnoea or other symptoms suggestive of cardiac disease during methylphenidate treatment should undergo a prompt specialist cardiac evaluation.
Analyses of data from clinical trials of methylphenidate in children and adolescents with ADHD showed that patients using methylphenidate may commonly experience changes in diastolic and systolic blood pressure of over 10 mmHg relative to controls. Increases in diastolic and systolic blood pressure values were also observed in clinical trial data from adult ADHD patients. The short- and long-term clinical consequences of these cardiovascular effects in children and adolescents are not known. The possibility of clinical complications cannot be excluded as a result of the effects observed in the clinical trial data especially when treatment during childhood/adolescence is continued into adulthood. \*\*Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate.\*\* See section 4.3 for conditions in which methylphenidate treatment is contraindicated.
\*\*Cardiovascular status should be carefully monitored. Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months\*\*. \*\*Methylphenidate should be discontinued in patients under treatment with repeated measures of tachycardia, arrhythmia or increased systolic blood pressure (>95th percentile) and referral to a cardiologist should be considered.\*\*
The use of methylphenidate is contraindicated in certain pre-existing cardiovascular disorders \*\*unless specialist cardiac advice has been obtained (see section 4.3).\*\*
\*Sudden death and pre-existing structural cardiac abnormalities or other serious cardiac disorders\*
Sudden death has been reported in association with the use of stimulants of the central nervous system at usual doses in patients, some of whom had structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone may carry an increased risk of sudden death, stimulant products are not recommended in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a medicinal product.
\*Adults\*
Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant medicinal products at usual doses for ADHD. Although the role of stimulants in these adult cases is unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs.
\*Misuse and cardiovascular events\*
Misuse of stimulants of the central nervous system may be associated with sudden death and other serious cardiovascular adverse events.
\*\*Cerebrovascular disorders\*\*
See section 4.3 for cerebrovascular conditions in which methylphenidate treatment is contraindicated. Patients with additional risk factors (such as a history of cardiovascular disease, concomitant medications that elevate blood pressure) should be assessed at every visit for neurological signs and symptoms after initiating treatment with methylphenidate.
Cerebral vasculitis appears to be a very rare idiosyncratic reaction to methylphenidate exposure. There is little evidence to suggest that patients at higher risk can be identified and the initial onset of symptoms may be the first indication of an underlying clinical problem. Early diagnosis, based on a high index of suspicion, may allow the prompt withdrawal of methylphenidate and early treatment. The diagnosis should therefore be considered in any patient who develops new neurological symptoms that are consistent with cerebral ischemia during methylphenidate therapy. These symptoms could include severe headache, numbness, weakness, paralysis, and impairment of coordination, vision, speech, language or memory.
Treatment with methylphenidate is not contraindicated in patients with hemiplegic cerebral palsy.
\*\*Psychiatric disorders\*\*
Co-morbidity of psychiatric disorders in ADHD is common and should be taken into account when prescribing stimulant medicinal products. Before the start of treatment with methylphenidate, the patient should be examined for any existing psychiatric disorders and a family history with regard to psychiatric disorders should be obtained (see section 4.2). In the case of emergent psychiatric symptoms or exacerbation of pre-existing psychiatric disorders, methylphenidate should not be given unless the benefits outweigh the risks to the patient.
\*\*Development or worsening of psychiatric disorders should be monitored at every adjustment of dose, then at least every 6 months, and at every visit; discontinuation of treatment may be appropriate.\*\*
\*Exacerbation of pre-existing psychotic or manic symptoms\*
In psychotic patients, administration of methylphenidate may exacerbate symptoms of behavioural disturbance and thought disorder.
\*Emergence of new psychotic or manic symptoms\*
Treatment-emergent psychotic symptoms (visual/tactile/auditory hallucinations and delusions) or mania in patients without prior history of psychotic illness or mania can be caused by methylphenidate at usual doses (see section 4.8). If manic or psychotic symptoms occur, consideration should be given to a possible causal role for methylphenidate, and discontinuation of treatment may be appropriate.
\*Aggressive or hostile behaviour\*
The emergence or worsening of aggression or hostility can be caused by treatment with stimulants. Aggression has been reported in patients treated with methylphenidate (see section 4.8). Patients treated with methylphenidate should be closely monitored for the emergence or worsening of aggressive behaviour or hostility at treatment initiation, at every dose adjustment and then at least every 6 months and every visit. Physicians should evaluate the need for adjustment of the treatment regimen in patients experiencing behaviour changes bearing in mind that upwards or downwards titration may be appropriate. Treatment interruption can be considered.
\*Suicidal tendency\*
Patients with emergent suicidal ideation or behaviour during treatment for ADHD should be evaluated immediately by their physician. Consideration should be given to the exacerbation of an underlying psychiatric condition and to a possible causal role of methylphenidate treatment. Treatment of an underlying psychiatric condition may be necessary and consideration should be given to a possible discontinuation of methylphenidate.
\*Tics\*
Methylphenidate is associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette's syndrome has also been reported (see section 4.8). Family history should be assessed and clinical evaluation for tics or Tourette's syndrome should precede use of methylphenidate. Patients should be regularly monitored for the emergence or worsening of tics during treatment with methylphenidate. Monitoring should be at every adjustment of dose and then at least every 6 months or every visit.
\*Anxiety, agitation or tension\*
Anxiety, agitation and tension have been reported in patients treated with methylphenidate (see section 4.8). Methylphenidate is associated with the worsening of pre-existing anxiety, agitation or tension. Anxiety has led to discontinuation of methylphenidate in some patients. Clinical evaluation for anxiety, agitation or tension should precede use of methylphenidate and patients should be \*\*regularly monitored for the emergence or worsening of these symptoms during treatment, at every adjustment of dose and then at least every 6 months or every visit.\*\*
\*Forms of bipolar disorder\*
Particular care should be taken in using methylphenidate to treat ADHD in patients with comorbid bipolar disorder (including untreated Type I Bipolar Disorder or other forms of bipolar disorder) because of concern for possible precipitation of a mixed/manic episode in such patients. Prior to initiating treatment with methylphenidate, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. \*\*Close ongoing monitoring is essential in these patients (see above 'Psychiatric Disorders' and section 4.2). Patients should be monitored for symptoms at every adjustment of dose, then at least every 6 months and at every visit.\*\*
\*\*Growth\*\*
Moderately reduced weight gain and growth retardation have been reported with the long-term use of methylphenidate in children. Weight decrease has been reported with methylphenidate treatment in adults (see section 4.8).
The effects of methylphenidate on final height and final weight are currently unknown and being studied.
\*\*Growth should be monitored during methylphenidate treatment: height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart.\*\* Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted. In adults, weight should be regularly monitored.
\*\*Seizures\*\*
Methylphenidate should be used with caution in patients with epilepsy. Methylphenidate may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and rarely in patients without a history of convulsions and no EEG abnormalities. If seizure frequency increases or new- onset seizures occur, methylphenidate should be discontinued.
\*\*Abuse, misuse and diversion\*\*
Patients should be carefully monitored for the risk of diversion, misuse and abuse of methylphenidate. Methylphenidate should be used with caution in patients with known drug or alcohol dependency because of a potential for abuse, misuse or diversion.
Chronic abuse of methylphenidate can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially in response to parenteral abuse.
Patient age, the presence of risk factors for substance use disorder (such as co-morbid oppositional-defiant or conduct disorder and bipolar disorder), previous or current substance abuse should all be taken into account when deciding on a course of treatment for ADHD. Caution is called for in emotionally unstable patients, such as those with a history of drug or alcohol dependence, because such patients may increase the dosage on their own initiative.
For some high-risk substance abuse patients, methylphenidate or other stimulants may not be suitable and non- stimulant treatment should be considered.
\*\*Priapism.\*\*
Prolonged and painful erections have been reported in association with methylphenidate products, mainly in association with a change in the methylphenidate treatment regimen. Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.
\*\*Use with serotonergic medicinal products\*\*
Serotonin syndrome has been reported following co-administration of methylphenidate with serotonergic medicinal products. If concomitant use of methylphenidate with a serotonergic medicinal product is warranted, prompt recognition of the symptoms of serotonin syndrome is important. These symptoms may include mental-status changes (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g. hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea). Methylphenidate must be discontinued as soon as possible if serotonin syndrome is suspected.
\*\*Withdrawal\*\*
Careful supervision is required during methylphenidate withdrawal, since this may unmask depression as well as chronic over- activity. Some patients may require long-term follow up.
Careful supervision is required during withdrawal from abusive use since severe depression may occur.
\*\*Fatigue\*\*
Methylphenidate should not be used for the prevention or treatment of normal fatigue states.
\*\*Choice of methylphenidate formulation\*\*
The choice of formulation of methylphenidate-containing medicinal product will have to be decided by the treating specialist on an individual basis and depends on the intended duration of effect.
\*\*Drug screening\*\*
This medicinal product contains methylphenidate which may induce a false positive laboratory test for amphetamines, particularly with immunoassay screen test. Athletes must be aware that this medicinal product may cause a positive reaction to 'anti-doping' tests.
\*\*Renal or hepatic impairment\*\*
There is no experience with the use of methylphenidate in patients with renal or hepatic impairment.
\*\*Haematological effects\*\*
The long-term safety of treatment with methylphenidate is not fully known. In the event of leukopenia, thrombocytopenia, anaemia or other alterations, including those indicative of serious renal or hepatic disorders, discontinuation of treatment should be considered (see section 4.8).
\*\*Administration\*\*
Due to the prolonged-release design of the tablet, Xaggitin XL should only be used in patients who are able to swallow the tablet whole. Patients should be informed that Xaggitin XL must be swallowed whole with the aid of liquids. Tablets should not be chewed, broken, divided, or crushed.
\*\*Excipient\*\*
\*\*\*Lactose\*\*\*
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Pharmacokinetic interaction\*\*
It is not known how methylphenidate may effect plasma concentrations of concomitantly administered medicinal products. Therefore, caution is recommended at combining methylphenidate with other medicinal products, especially those with a narrow therapeutic window.
Methylphenidate is not metabolised by cytochrome P450 to a clinically relevant extent. Inducers or inhibitors of cytochrome P450 are not expected to have any relevant impact on methylphenidate pharmacokinetics. Conversely, the d- and l- enantiomers of methylphenidate do not relevantly inhibit cytochrome P450 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A.
However, there are reports indicating that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (e.g., phenobarbital, phenytoin, primidone), and some antidepressants (tricyclics and selective serotonin reuptake inhibitors). When starting or stopping treatment with methylphenidate, it may be necessary to adjust the dosage of these medicinal products already being taken and establish plasma concentrations (or for coumarin, coagulation times).
\*\*Pharmacodynamic interactions\*\*
\*Anti-hypertensive medicinal products\*
Methylphenidate may decrease the effectiveness of medicinal products used to treat hypertension.
\*Use with medicinal products that elevate blood pressure\*
Caution is advised in patients being treated with methylphenidate with any other medicinal product that can also elevate blood pressure (see also sections on cardiovascular and cerebrovascular conditions in section 4.4).
Because of possible hypertensive crisis, methylphenidate is contraindicated in patients being treated (currently or within the preceding 2 weeks) with non-selective, irreversible MAO-inhibitors (see section 4.3).
\*Use with alcohol\*
Alcohol may exacerbate the adverse CNS effect of psychoactive medicinal products, including methylphenidate. It is therefore advisable for patients to abstain from alcohol during treatment.
\*Use with serotonergic medicinal products\*
There have been reports of serotonin syndrome following co-administration of methylphenidate with serotonergic medicinal products. If concomitant use of methylphenidate with a serotonergic medicinal product is warranted, prompt recognition of the symptoms of serotonin syndrome is important (see section 4.4). Methylphenidate must be discontinued as soon as possible if serotonin syndrome is suspected.
\*Use with halogenated anaesthetics\*
There is a risk of sudden blood pressure and heart rate increase during surgery. If surgery is planned, methylphenidate treatment should not be used on the day of surgery.
\*Use with centrally acting alpha-2 agonists (e.g. clonidine)\*
Serious, adverse events, including sudden death, have been reported in concomitant use of methylphenidate and clonidine. The long-term safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systematically evaluated.
\*Use with dopaminergic medicinal products\*
Caution is recommended when administering methylphenidate with dopaminergic medicinal products, including antipsychotics. Because a predominant action of methylphenidate is to increase extracellular dopamine levels, methylphenidate may be associated with pharmacodynamic interactions when co-administered with direct and indirect dopamine agonists (including DOPA and tricyclic antidepressants) or with dopamine antagonists including antipsychotics.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Data from a cohort study of in total approximately 3,400 pregnancies exposed in the first trimester do not suggest an increased risk of overall birth defects. There was a small increased occurrence of cardiac malformations (pooled adjusted relative risk, 1.3; 95 % CI, 1.0-1.6) corresponding to 3 additional infants born with congenital cardiac malformations for every 1000 women who receive methylphenidate during the first trimester of pregnancy, compared with non-exposed pregnancies.
Cases of neonatal cardiorespiratory toxicity, specifically foetal tachycardia and respiratory distress have been reported in spontaneous case reports.
Studies in animals have shown evidence of reproductive toxicity at maternally toxic doses (see section 5.3). Methylphenidate is not recommended for use during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy
\*\*Breast-feeding\*\*
Methylphenidate is excreted in human milk. Based on reports of breast milk sampling from five mothers, methylphenidate concentrations in human milk resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage, and a milk to maternal plasma ratio ranging between 1.1 and 2.7.
There is one case report of an infant who experienced an unspecified decrease in weight during the period of exposure but recovered and gained weight after the mother discontinued treatment with methylphenidate. A risk to the suckling child cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from methylphenidate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
\*\*Fertility\*\*
No human data on the effect of methylphenidate on fertility are available. There were no relevant effects observed in the non-clinical studies.4.7 Effects on ability to drive and use machines
Methylphenidate can cause dizziness, drowsiness and visual disturbances including difficulties with accommodation, diplopia and blurred vision. It may have a moderate influence on the ability to drive and use machines. Patients should be warned of these possible effects and advised that if affected, they should avoid potentially hazardous activities such as driving or operating machinery.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
| | |
| --- | --- |
| | - The medicine has been prescribed to treat a medical or dental problem and - You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and - It was not affecting your ability to drive safely. |4.8 Undesirable effects
The table below shows all adverse reactions observed during clinical trials of children, adolescents, and adults and post-market spontaneous reports with methylphenidate prolonged-release tablets and those, which have been reported with other methylphenidate hydrochloride formulations. If the adverse with methylphenidate prolonged-release tablets and the methylphenidate formulation frequencies were different, the highest frequency of both databases was used.
Frequency estimate:
Very common (≥ 1/10)
Common (≥ 1/100 to < 1/10)
Uncommon (≥ 1/1,000 to < 1/100)
Rare (≥ 1/10,000 to < 1/1,000)
Very rare (< 1/10,000)
Not known (cannot be estimated from the available data).
| | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| System Organ Class | Adverse Reaction | | | | | |
| Frequency | | | | | |
| Very Common | Common | Uncommon | Rare | Very rare | Not known |
| Infections and infestations | | Nasopharyngitis, Upper respiratory tract infection#, Sinusitis# | | | | |
| Blood and lymphatic system disorders | | | | | Anaemia†, Leucopenia†, Thrombocytopenia, Thrombocytopenic purpura | Pancytopenia |
| Immune system disorders | | | Hypersensitivity reactions such as Angioneurotic oedema, Anaphylactic reactions, Auricular swelling, Bullous conditions, Exfoliative conditions, Urticarias, Pruritus, Rashes, and Eruptions | | | |
| Metabolism and nutrition disorders\\* | | Anorexia, Decreased appetite†, Moderately reduced weight and height gain during prolonged use in children\\* | | | | |
| Psychiatric disorders\\* | Insomnia, Nervousness | Affect lability, Aggression\\*, Agitation\\*, Anxiety\\*†, Depression\\*, #, Irritability, Abnormal behaviour, Mood swings, Tics\\*, Initial insomnia#, Depressed mood#, Libido decreased#, Tension#, Bruxism#, ‡, Panic attack# | Psychotic disorders\\*, Auditory, visual and tactile hallucination\\*, Anger, Suicidal ideation\\*, Mood altered, Restlessness†, Tearfulness, Worsening of pre-existing tics of Tourette's syndrome\\*, Logorrhoea, Hypervigilance, Sleep disorder | Mania\\*†, Disorientation, Libido disorder, Confusional state† | Suicidal attempt (including completed suicide) \\* †, Transient depressed mood\\*, Abnormal thinking, Apathy†, Repetitive behaviours, Over- focussing | Delusions\\*†, Thought disturbances\\*, Dependence. Cases of abuse and dependence have been described, more often with immediate release formulations |
| Nervous system disorders | Headache | Dizziness, Dyskinesia, Psychomotor hyperactivity, Somnolence, Paresthaesia#, Tension headache# | Sedation, Tremor†, Lethargy# | | Convulsion, Choreo-athetoid movements, Reversible ischaemic neurological deficit, Neuroleptic malignant syndrome (NMS; Reports were poorly documented and in most cases, patients were also receiving other medicinal products, so the role of methylphenidate is unclear). | Cerebrovascular disorders\\*† (including vasculitis, cerebral haemorrhages, cerebrovascular accidents, cerebral arteritis, cerebral occlusion), Grand mal convulsion\\*, Migraine†, Dysphemia |
| Eye disorders | | Accommodation disorder# | Blurred vision†, Dry eye# | Difficulties in visual accommodation, Visual impairment, Diplopia | | Mydriasis |
| Ear and labyrinth disorders | | Vertigo# | | | | |
| Cardiac disorders\\* | | Arrhythmia, Tachycardia, Palpitations | Chest pain | Angina pectoris | Cardiac arrest, Myocardial infarction | Supraventricular tachycardia, Bradycardia, Ventricular extrasystoles†, Extrasystoles† |
| Vascular disorders\\* | | Hypertension | Hot flush# | | Cerebral arteritis and/or occlusion, Peripheral coldness†, Raynaud's phenomenon | |
| Respiratory, thoracic and mediastinal disorders | | Cough, Oropharyngeal pain | Dyspnoea† | | | Epistaxis |
| Gastrointestinal disorders | | Abdominal pain upper, Diarrhoea, Nausea†, Abdominal discomfort, Vomiting, Dry mouth†, Dyspepsia# | Constipation† | | | |
| Hepatobiliary disorders | | Alanine aminotransferase increased# | Hepatic enzyme elevations | | Abnormal liver function, including Acute hepatic failure and hepatic coma, Blood alkaline phosphatase increased, Blood bilirubin increased† | |
| Skin and subcutaneous tissue disorders | | Alopecia, Hyperhidrosis†, Pruritis, Rash, Urticaria | Angioneurotic oedema, Bullous conditions, Exfoliative conditions | Macular rash; Erythema | Erythema multiforme, Exfoliative dermatitis, Fixed drug eruption | |
| Musculoskeletal and connective tissue disorders | | Arthralgia, Muscle tightness#, Muscle spasms# | Myalgia†, Muscle twitching | | Muscle cramps | Trismus‡ |
| Renal and urinary disorders | | | Haematuria, Pollakiuria | | | Incontinence |
| Reproductive system and breast disorders | | Erectile dysfunction# | | Gynaecomastia | | Priapism\\*, Erection increased\\* and Prolonged erection\\* |
| General disorders and administration site conditions | | Pyrexia, Growth retardation during prolonged use in children\\*, Fatigue†, Irritability#, Feeling jittery#, Asthenia#, Thirst# | Chest pain | | Sudden cardiac death\\* | Chest discomfort†, Hyperpyrexia |
| Investigations | | Changes in blood pressure and heart rate (usually an increase)\\*, Weight decreased\\*, Alanine aminotransferase increased# | Cardiac murmur\\* | | Platelet count decreased, White blood cell count abnormal | |
\\* See section 4.4
# Frequency derived from adult clinical trials and not on data from trials in children and adolescents; may also be relevant for children and adolescents.
† Adverse drug reaction from clinical trials in adult patients that were and reported with a higher frequency than in children and adolescents.
‡ Based on the frequency calculated in adult ADHD studies (no cases were reported in the paediatric studies).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
When treating patients with overdose, allowances must be made for the delayed release of methylphenidate from formulations with extended durations of action.
\*\*Signs and Symptoms\*\*
Acute overdose, mainly due to overstimulation of the central and sympathetic nervous systems, may result in vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, dryness of mucous membranes and rhabdomyolysis.
\*\*Treatment\*\*
There is no specific antidote to methylphenidate overdosage. Treatment consists of appropriate supportive measures.
The patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. The efficacy of activated charcoal has not been established.
Intensive care must be provided to maintain adequate circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia.
Efficacy of peritoneal dialysis or extracorporeal haemodialysis for overdose of methylphenidate has not been established.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: centrally acting sympathomimetics: ATC code: N06BA04
\*\*Mechanism of action\*\*
Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space. Methylphenidate is a racemic mixture comprised of the d- and l-isomers. The d-isomer is more pharmacologically active than the l-isomer.
\*\*Clinical efficacy and safety\*\*
\*\*\*Children\*\*\*
In the pivotal clinical studies, methylphenidate prolonged-release tablets were assessed in 321 paediatric patients already stabilised with immediate release preparations (IR) of methylphenidate and in 95 paediatric patients not previously treated with IR preparations of methylphenidate.
Clinical studies in paediatric patients showed that the effects of methylphenidate prolonged-release tablets were maintained until 12 hours after dosing when the product was taken once daily in the morning.
\*Adults\*
Short-term efficacy has been demonstrated for methylphenidate prolonged-release tablets in a dosage range of 18 to 72 mg/day. One thousand five hundred and twenty-three (1523) adults with ADHD aged 18 to 65 years were evaluated in five double-blind, placebo-controlled studies of 5 to 13 weeks duration. Methylphenidate prolonged-release tablets were evaluated in 2 fixed-dose studies and 3 flexible dose studies, using DSM-IV based instruments for the assessment of ADHD symptom severity in adults. In two fixed-dose studies, Conner's Adult ADHD Rating Scales (CAARS) showed that total scores of ADHD symptoms decreased, indicating an improvement in the severity of ADHD symptoms, from baseline to double-blind end point. In one fixed-dose study, all dose levels of methylphenidate prolonged-release tablets showed clinically significantly greater symptom control (p<0.05 for all dose levels), compared to placebo as measured by a reduction in CAARS total score. In the second fixed-dose study, methylphenidate prolonged-release tablets 72 mg/day but not methylphenidate prolonged-release tablets 54 mg/day, proved to be statistically significant over placebo in reducing the CAARS ADHD symptoms total score from baseline to double-blind end point among adult subjects with ADHD (p-value 0.0024).
In two flexible dose studies, the LS mean changes from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score at endpoint were statistically significant (Study 1: p = 0.012; Study 2: p<0.001) for final methylphenidate prolonged-release tablets dose treatment over placebo (Study 1: -10.6 for methylphenidate prolonged-release tablets vs -6.8 placebo; Study 2: -16.9 for methylphenidate prolonged-release tablets vs -12.0 for placebo). In the third flexible dose study (Study 3), methylphenidate prolonged-release tablets showed clinically significantly greater symptom control (p<0.0001) compared to placebo as measured by a reduction in CAARS total score. The LS mean change from baseline to Final Visit (Week 8) in the total ADHD Symptoms Scores of CAARS-O:SV was -10.9 in the methylphenidate prolonged-release tablets group and -6.9 in the placebo group (based on the ITT population).
In flexible dose Study 2, the magnitude of improvement in the total AISRS scores was statistically significantly larger in the methylphenidate prolonged-release tablets group than in the placebo group (p = 0.0037). The LS mean (95% CI) difference from placebo was -5.3 (-8.9, -1.7). In flexible dose Study 3, the magnitude of improvement in the CAARS-O:SV scores was statistically significantly larger in the methylphenidate prolonged-release tablets group than in the placebo group (p = 0.0063). The LS mean (95% CI) difference from placebo was -3.9 (-6.6, -1.1).
Adults treated with methylphenidate prolonged-release tablets in four long-term open-label studies over 6 to 12 months showed improvement in all efficacy endpoints evaluated, indicating stable effects over time on the reduction in ADHD symptoms. In one open-label study in a community setting, methylphenidate prolonged-release tablets treatment for up to 9 months showed improvement from baseline values in mean global assessment of efficacy scores by both the patient and the investigator. In a second study, in which adults with ADHD received methylphenidate prolonged-release tablets for up to 1 year with a mean final dose of 67.4 mg/day showed clinically meaningful improvements from baseline in AISRS total scores with a mean change of -18.7 at the final visit. In a third long-term study of 48 weeks, adults with ADHD received methylphenidate prolonged-release tablets with a mean final dose of 46.6 mg/day showed a change from baseline in the mean DSM-IV Total ADHD symptoms score of CAARS by -17.2 at endpoint. In the fourth study, methylphenidate prolonged-release tablets were evaluated in a 52-week open label study in subjects who had previously completed a short-term placebo-controlled trial and short-term open-label extension. Adults with ADHD received methylphenidate prolonged-release tablets with a mean final dose of 53.8 mg/day showed stable effects over time on reductions in ADHD symptoms. Investigator-rated CAARS improved throughout the open-label phase and was lower at endpoint (mean decrease by 1.9 from baseline).5.2 Pharmacokinetic properties
\*\*Absorption\*\*
Methylphenidate is readily absorbed. Following oral administration of methylphenidate prolonged-release tablets to adults the tablet coating dissolves, providing an initial maximum methylphenidate concentration at about 1 to 2 hours. The methylphenidate contained in the tablet core is gradually released over the next several hours. Peak plasma concentrations are achieved at about 6 to 8 hours, after which plasma levels of methylphenidate gradually decrease. Methylphenidate prolonged-release tablets taken once daily minimises the fluctuations between peak and trough concentrations associated with immediate-release methylphenidate three times daily. The extent of absorption of methylphenidate prolonged-release tablets once daily is generally comparable to conventional immediate release preparations.
Following the administration of methylphenidate prolonged-release tablets 18 mg once daily in 36 adults, the mean pharmacokinetic parameters were: Cmax 3.7 ± 1.0 (ng/mL), tmax 6.8 ± 1.8 (h), AUCinf 41.8 ± 13.9 (ng.h/mL), and t½ 3.5 ± 0.4 (h).
No differences in the pharmacokinetics of methylphenidate prolonged-release tablets were noted following single and repeated once daily dosing, indicating no significant methylphenidate accumulation. The AUC and t½ following repeated once daily dosing are similar to those following the first dose of methylphenidate prolonged-release tablets 18 mg.
Following administration of methylphenidate prolonged-release tablets in single doses of 18 to 72 mg/day to adults, Cmax and AUCinf of methylphenidate were proportional to dose.
\*\*Distribution\*\*
Plasma methylphenidate concentrations in adults decline biexponentially following oral administration. The half-life of methylphenidate in adults following oral administration of methylphenidate prolonged-release tablets was approximately 3.5 h. The rate of protein binding of methylphenidate and of its metabolites is approximately 15%. The apparent volume of distribution of methylphenidate is approximately 13 litres/kg.
\*\*Biotransformation\*\*
In humans, methylphenidate is metabolised primarily by de-esterification to alpha-phenyl-piperidine acetic acid (PPA, approximately 50 fold the level of the unchanged substance) which has little or no pharmacologic activity. In adults the metabolism of methylphenidate prolonged-release tablets once daily as evaluated by metabolism to PPA is similar to that of methylphenidate three times daily. The metabolism of single and repeated once daily doses of methylphenidate prolonged-release tablets is similar.
\*\*Elimination\*\*
The elimination half-life of methylphenidate in adults following administration of methylphenidate prolonged-release tablets was approximately 3.5 hours. After oral administration, about 90% of the dose is excreted in urine and 1 to 3% in faeces, as metabolites within 48 to 96 hours. Small quantities of unchanged methylphenidate are recovered in urine (less than 1%). The main urinary metabolite is alpha-phenyl-piperidine acetic acid (60-90%).
After oral dosing of radiolabelled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was PPA, accounting for approximately 80% of the dose.
\*\*Food effects\*\*
In patients, there were no differences in either the pharmacokinetics or the pharmacodynamic performance of methylphenidate prolonged-release tablets when administered after a high fat breakfast on an empty stomach.
\*\*Special populations\*\*
\*Gender\*
In healthy adults, the mean dose-adjusted AUCinf values for methylphenidate prolonged-release tablets were 36.7 ng.h/mL in men and 37.1 ng.h/mL in women, with no differences noted between the two groups.
\*Race\*
In healthy adults receiving methylphenidate prolonged-release tablets, dose-adjusted AUCinf was consistent across ethnic groups; however, the sample size may have been insufficient to detect ethnic variations in pharmacokinetics.
\*Age\*
The pharmacokinetics of methylphenidate prolonged-release tablets has not been studied in children younger than 6 years of age. In children 7-12 years of age, the pharmacokinetics of methylphenidate prolonged-release tablets after 18, 36 and 54 mg were (mean±SD): Cmax 6.0 ± 1.3, 11.3 ± 2.6, and 15.0 ± 3.8 ng/mL, respectively, tmax 9.4 ± 0.02, 8.1 ± 1.1, 9.1 ± 2.5 h, respectively, and AUC0-11.5 50.4 ± 7.8, 87.7 ± 18.2, 121.5 ± 37.3 ng.h/mL, respectively.
\*Renal impairment\*
There is no experience with the use of methylphenidate prolonged-release tablets in patients with renal impairment. After oral administration of radiolabelled methylphenidate in humans, methylphenidate was extensively metabolised and approximately 80% of the radioactivity was excreted in the urine in the form of PPA. Since renal clearance is not an important route of methylphenidate clearance, renal impairment is expected to have little effect on the pharmacokinetics of methylphenidate prolonged-release tablets.
\*Hepatic impairment\*
There is no experience with the use of methylphenidate prolonged-release tablets in patients with hepatic impairment.5.3 Preclinical safety data
\*\*Carcinogenicity\*\*
In life-time rat and mouse carcinogenicity studies, increased numbers of malignant liver tumours were noted in male mice only. The significance of this finding to humans is unknown.
Methylphenidate did not affect reproductive performance or fertility at low multiples of the clinical dose.
\*\*Pregnancy-embryonal/foetal development\*\*
Methylphenidate is not considered to be teratogenic in rats and rabbits. Foetal toxicity (i.e. total litter loss) and maternal toxicity was noted in rats at maternally toxic doses.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Tablet core\*\*
Lactose monohydrate
Hypromellose
Silica, colloidal anhydrous
Magnesium stearate
Fumaric acid
Methacrylic acid–methyl methacrylate copolymer
Triethyl citrate
Talc
\*\*Tablet coating\*\*
\*18 mg prolonged-release tablets:\*
Polyvinyl alcohol, part hydrolyzed
Macrogol (3350)
Talc
Titanium dioxide (E171)
Iron oxide yellow (E172)
Iron oxide red (E172)
\*27 mg prolonged-release tablets:\*
Polyvinyl alcohol, part hydrolyzed
Macrogol (3350)
Talc
Titanium dioxide (E171)
Iron oxide yellow (E172)
Indigo carmine aluminium lake (E132)
Iron oxide black (E172)
\*36 mg prolonged-release tablets:\*
Polyvinyl alcohol, part hydrolyzed
Macrogol (3350)
Talc
Titanium dioxide (E171)
\*54 mg prolonged-release tablets:\*
Polyvinyl alcohol, part hydrolyzed
Macrogol (3350)
Talc
Titanium dioxide (E171)
Iron oxide red (E172)
\*\*Printing ink\*\*
Shellac glaze
Iron oxide black (E172)
Propylene glycol6.2 Incompatibilities
Not applicable.6.3 Shelf life
2 years
Shelf life after first opening the bottle:
18 mg tablets: 3 months
27 mg tablets: 6 months
36 mg tablets: 6 months
54 mg tablets: 6 months6.4 Special precautions for storage
This medicinal product does not require any special storage conditions6.5 Nature and contents of container
HDPE bottle with a child-resistant PP closure with silica gel desiccant integrated into the closure.
18 mg tablets: 28, 29, 30 or 90 prolonged-release tablets.
27 mg tablets: 28, 29, 30 or 100 prolonged-release tablets.
36 mg tablets: 28, 29, 30 or 100 prolonged-release tablets.
54 mg tablets: 28, 29, 30 or 100 prolonged-release tablets.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
No special requirements
- Instruction Content
- ## Pharmaceutical Form
Prolonged-release tablet.
18 mg Tablet: Capsule-shaped, biconvex, yellow tablet, 6.6 mm x 11.9 mm, with “2392” printed on one side in black ink.
27 mg Tablet: Capsule-shaped, biconvex, grey tablet, 6.7 mm x 12.0 mm, with “2393” printed on one side in black ink.
36 mg Tablet: Capsule-shaped, biconvex, white tablet, 6.7 mm x 12.0 mm, with “2394” printed on one side in black ink.
54 mg Tablet: Capsule-shaped, biconvex, red-brown tablet, 6.8 mm x 12.0 mm, with “2395” printed on one side in black ink
## Clinical Particulars
4.1 Therapeutic indications
\*\*Attention-Deficit/Hyperactivity Disorder (ADHD)\*\*
Xaggitin XL is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over and adults when remedial measures alone prove insufficient. Treatment must be initiated and supervised by a physician specialised in the treatment of ADHD such as an expert paediatrician, a child and adolescent psychiatrist or an adult psychiatrist.
Special Diagnostic Considerations for ADHD in children
Diagnosis should be made according to the current DSM criteria or ICD guidelines and should be based on a complete history and evaluation of the patient. Third-party corroboration is desirable and diagnosis cannot be made solely on the presence of one or more symptom.
The specific aetiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and specialised psychological, educational, and social resources.
A comprehensive treatment programme typically includes psychological, educational and social measures as well as pharmacotherapy and is aimed at stabilising children with a behavioural syndrome characterised by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impaired.
Methylphenidate treatment is not indicated in all children with ADHD and the decision to use the medicinal product must be based on a very thorough assessment of the severity and chronicity of the child's symptoms in relation to the child's age.
Appropriate educational placement is essential, and psychosocial intervention is generally necessary. Where remedial measures alone prove insufficient, the decision to prescribe a stimulant must be based on rigorous assessment of the severity of the child's symptoms. The use of methylphenidate should always be used in this way according to the licensed indication and according to prescribing/diagnostic guidelines.
Special Diagnostic Considerations for ADHD in adults
Diagnosis should be made according to the current DSM criteria or ICD guidelines, and should be based on a complete history and evaluation of the patient.
The specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adults with ADHD have symptom patterns characterised by restlessness, impatience, and inattentiveness. Symptoms such as hyperactivity tend to diminish with increasing age, possibly due to adaptation, neurodevelopment and self-medication. Inattentive symptoms are more prominent and have a greater impact on adults with ADHD. Diagnosis in adults should include a structured patient interview to determine current symptoms. The pre-existence of childhood ADHD is required and has to be determined retrospectively (by patient's records or, if not available, by appropriate and structured instruments/interviews). Third-party corroboration is desirable and treatment should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis should not be made solely on the presence of one or more symptoms. The decision to use a stimulant in adults must be based on a very thorough assessment and diagnosis should include moderate or severe functional impairment in at least 2 settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual's life.4.2 Posology and method of administration
Treatment must be initiated and supervised by a physician specialised in the treatment of ADHD such as an expert paediatrician, a child and adolescent psychiatrist or an adult psychiatrist.
\*\*Pre-treatment screening\*\*
In adults new to Xaggitin XL, and if required by national practice, cardiologist advice is needed prior to treatment initiation in order to check the absence of cardiovascular contraindications.
Prior to prescribing, it is necessary to conduct a baseline evaluation of a patient's cardiovascular status including blood pressure and heart rate. A comprehensive history should document concomitant medications, past and present co-morbid medical and psychiatric disorders or symptoms, family history of sudden cardiac/unexplained death and accurate recording of pre-treatment height and weight on a growth chart (see sections 4.3 and 4.4).
\*\*Ongoing monitoring\*\*
Growth, psychiatric and cardiovascular status should be continuously monitored (see also section 4.4).
• Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months;
• Height, weight and appetite in children should be recorded at least 6 monthly with maintenance of a growth chart;
• Weight should be recorded for adults regularly;
• Development of de novo or worsening of pre-existing psychiatric disorders should be monitored at every adjustment of dose and then at least every 6 months and at every visit.
Patients should be monitored for the risk of diversion, misuse and abuse of methylphenidate.
\*Dose titration\*
Careful dose titration is necessary at the start of treatment with methylphenidate. Dose titration should be started at the lowest possible dose. A 27 mg dosage strength is available for those who wish to prescribe between the 18 mg and 36 mg dosages.
For doses not realisable/practicable with this medicinal product, other strengths and medicinal products are available.
Dosage may be adjusted in 18 mg increments. In general, dosage adjustment may proceed at approximately weekly intervals.
\*Children\*
The maximum daily dosage is 54 mg.
\*Adults\*
The maximum daily dosage is 72 mg.
\*\*Posology\*\*
\*Children/ adults new to methylphenidate\*
Xaggitin XL may not be indicated in all children/adults with ADHD syndrome. Lower doses of short-acting methylphenidate formulations may be considered sufficient to treat children/adults new to methylphenidate. Careful dose titration by the physician in charge is required in order to avoid unnecessarily high doses of methylphenidate. The recommended starting dose of Xaggitin XL for children/adults who are not currently taking methylphenidate, or for children/adults who are on stimulants other than methylphenidate, is 18 mg once daily.
\*Patients currently using methylphenidate\*
The recommended dose of Xaggitin XL for patients who are currently taking methylphenidate three times daily at doses of 15 to 60 mg/day is provided in Table 1. Dosing recommendations are based on current dose regimen and clinical judgement.
TABLE 1
Recommended dose conversion from other methylphenidate hydrochloride regimens, where available, to Xaggitin XL
| | |
| --- | --- |
| Previous methylphenidate hydrochloride daily dose | Recommended Xaggitin XL dose |
| 5 mg three times daily | 18 mg once daily |
| 10 mg three times daily | 36 mg once daily |
| 15 mg three times daily | 54 mg once daily |
| 20 mg three times daily | 72 mg once daily |
If improvement is not observed after appropriate dosage adjustment over a one-month period, the medicinal product should be discontinued.
\*\*Long-term (more than 12 months) use\*\*
The safety and efficacy of long-term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. In children and adolescents, methylphenidate treatment is usually discontinued during or after puberty. The physician who elects to use methylphenidate for extended periods (over 12 months) in patients with ADHD should periodically re-evaluate the long-term usefulness of the medicinal product for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy.
It is recommended that methylphenidate is de-challenged at least once yearly to assess the patient's condition (for children, preferably during times of school holidays). Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued.
\*\*Dose reduction and discontinuation\*\*
Treatment must be stopped if the symptoms do not improve after appropriate dosage adjustment over a one-month period. If paradoxical aggravation of symptoms or other serious adverse events occur, the dosage should be reduced or discontinued.
\*\*Special populations\*\*
\*Elderly\*
Methylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group. Methylphenidate has not been studied in ADHD in patients older than 65 years.
\*Hepatic or renal impairment\*
Methylphenidate has not been studied in patients with hepatic or renal impairment.
\*Children under 6 years of age\*
Methylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.
\*\*Method of administration\*\*
Xaggitin XL is for oral use once daily in the morning.
Xaggitin XL may be administered with or without food (see section 5.2).
The prolonged-release tablets must be swallowed whole with the aid of liquids, and must not be chewed, broken divided, or crushed (see section 4.4).4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Glaucoma
• Phaeochromocytoma
• During treatment with non-selective, irreversible monoamine oxidase (MAO) inhibitors, or within a minimum of 14 days of discontinuing those medicinal products, due to the risk of hypertensive crisis (see section 4.5)
• Hyperthyroidism or thyrotoxicosis
• Diagnosis or history of severe depression, anorexia nervosa/anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic/borderline personality disorder
• Diagnosis or history of severe and episodic (Type I) Bipolar (affective) Disorder (that is not well-controlled)
• Pre-existing cardiovascular disorders including severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life- threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels)
• Pre-existing cerebrovascular disorders cerebral aneurysm, vascular abnormalities including vasculitis or stroke4.4 Special warnings and precautions for use
Methylphenidate treatment is not indicated in all patients with ADHD and the decision to use the medicinal product must be based on a very thorough assessment of the severity and chronicity of the patient's symptoms. When treatment of children is considered, assessment of the severity and chronicity of the child's symptoms should be related to the child's age (6-18 years).
\*\*Long-term use (more than 12 months)\*\*
The safety and efficacy of long-term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. In children and adolescents, methylphenidate treatment is usually discontinued during or after puberty. Patients on long-term therapy (i.e. over 12 months) must have careful ongoing monitoring according to the guidance in sections 4.2 and 4.4 for cardiovascular status, growth (children), weight, appetite, development of de novo or worsening of pre-existing psychiatric disorders. Psychiatric disorders to monitor for are described below, and include (but are not limited to) motor or vocal tics, aggressive or hostile behaviour, agitation, anxiety, depression, psychosis, mania, delusions, irritability, lack of spontaneity, withdrawal and excessive perseveration.
The physician who elects to use methylphenidate for extended periods (over 12 months) should periodically re-evaluate the long-term usefulness of the medicinal product for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the patient's condition (for children, preferably during times of school holidays). Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued.
\*\*Use in the elderly\*\*
Methylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group. Methylphenidate has not been studied in ADHD in patients older than 65 years.
\*\*Use in children under 6 years of age\*\*
Methylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.
\*\*Cardiovascular status\*\*
Patients who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden cardiac or unexplained death or malignant arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further specialist cardiac evaluation if initial findings suggest such history or disease. Patients who develop symptoms such as palpitations, exertional chest pain, unexplained syncope, dyspnoea or other symptoms suggestive of cardiac disease during methylphenidate treatment should undergo a prompt specialist cardiac evaluation.
Analyses of data from clinical trials of methylphenidate in children and adolescents with ADHD showed that patients using methylphenidate may commonly experience changes in diastolic and systolic blood pressure of over 10 mmHg relative to controls. Increases in diastolic and systolic blood pressure values were also observed in clinical trial data from adult ADHD patients. The short- and long-term clinical consequences of these cardiovascular effects in children and adolescents are not known. The possibility of clinical complications cannot be excluded as a result of the effects observed in the clinical trial data especially when treatment during childhood/adolescence is continued into adulthood. \*\*Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate.\*\* See section 4.3 for conditions in which methylphenidate treatment is contraindicated.
\*\*Cardiovascular status should be carefully monitored. Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months\*\*. \*\*Methylphenidate should be discontinued in patients under treatment with repeated measures of tachycardia, arrhythmia or increased systolic blood pressure (>95th percentile) and referral to a cardiologist should be considered.\*\*
The use of methylphenidate is contraindicated in certain pre-existing cardiovascular disorders \*\*unless specialist cardiac advice has been obtained (see section 4.3).\*\*
\*Sudden death and pre-existing structural cardiac abnormalities or other serious cardiac disorders\*
Sudden death has been reported in association with the use of stimulants of the central nervous system at usual doses in patients, some of whom had structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone may carry an increased risk of sudden death, stimulant products are not recommended in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a medicinal product.
\*Adults\*
Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant medicinal products at usual doses for ADHD. Although the role of stimulants in these adult cases is unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs.
\*Misuse and cardiovascular events\*
Misuse of stimulants of the central nervous system may be associated with sudden death and other serious cardiovascular adverse events.
\*\*Cerebrovascular disorders\*\*
See section 4.3 for cerebrovascular conditions in which methylphenidate treatment is contraindicated. Patients with additional risk factors (such as a history of cardiovascular disease, concomitant medications that elevate blood pressure) should be assessed at every visit for neurological signs and symptoms after initiating treatment with methylphenidate.
Cerebral vasculitis appears to be a very rare idiosyncratic reaction to methylphenidate exposure. There is little evidence to suggest that patients at higher risk can be identified and the initial onset of symptoms may be the first indication of an underlying clinical problem. Early diagnosis, based on a high index of suspicion, may allow the prompt withdrawal of methylphenidate and early treatment. The diagnosis should therefore be considered in any patient who develops new neurological symptoms that are consistent with cerebral ischemia during methylphenidate therapy. These symptoms could include severe headache, numbness, weakness, paralysis, and impairment of coordination, vision, speech, language or memory.
Treatment with methylphenidate is not contraindicated in patients with hemiplegic cerebral palsy.
\*\*Psychiatric disorders\*\*
Co-morbidity of psychiatric disorders in ADHD is common and should be taken into account when prescribing stimulant medicinal products. Before the start of treatment with methylphenidate, the patient should be examined for any existing psychiatric disorders and a family history with regard to psychiatric disorders should be obtained (see section 4.2). In the case of emergent psychiatric symptoms or exacerbation of pre-existing psychiatric disorders, methylphenidate should not be given unless the benefits outweigh the risks to the patient.
\*\*Development or worsening of psychiatric disorders should be monitored at every adjustment of dose, then at least every 6 months, and at every visit; discontinuation of treatment may be appropriate.\*\*
\*Exacerbation of pre-existing psychotic or manic symptoms\*
In psychotic patients, administration of methylphenidate may exacerbate symptoms of behavioural disturbance and thought disorder.
\*Emergence of new psychotic or manic symptoms\*
Treatment-emergent psychotic symptoms (visual/tactile/auditory hallucinations and delusions) or mania in patients without prior history of psychotic illness or mania can be caused by methylphenidate at usual doses (see section 4.8). If manic or psychotic symptoms occur, consideration should be given to a possible causal role for methylphenidate, and discontinuation of treatment may be appropriate.
\*Aggressive or hostile behaviour\*
The emergence or worsening of aggression or hostility can be caused by treatment with stimulants. Aggression has been reported in patients treated with methylphenidate (see section 4.8). Patients treated with methylphenidate should be closely monitored for the emergence or worsening of aggressive behaviour or hostility at treatment initiation, at every dose adjustment and then at least every 6 months and every visit. Physicians should evaluate the need for adjustment of the treatment regimen in patients experiencing behaviour changes bearing in mind that upwards or downwards titration may be appropriate. Treatment interruption can be considered.
\*Suicidal tendency\*
Patients with emergent suicidal ideation or behaviour during treatment for ADHD should be evaluated immediately by their physician. Consideration should be given to the exacerbation of an underlying psychiatric condition and to a possible causal role of methylphenidate treatment. Treatment of an underlying psychiatric condition may be necessary and consideration should be given to a possible discontinuation of methylphenidate.
\*Tics\*
Methylphenidate is associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette's syndrome has also been reported (see section 4.8). Family history should be assessed and clinical evaluation for tics or Tourette's syndrome should precede use of methylphenidate. Patients should be regularly monitored for the emergence or worsening of tics during treatment with methylphenidate. Monitoring should be at every adjustment of dose and then at least every 6 months or every visit.
\*Anxiety, agitation or tension\*
Anxiety, agitation and tension have been reported in patients treated with methylphenidate (see section 4.8). Methylphenidate is associated with the worsening of pre-existing anxiety, agitation or tension. Anxiety has led to discontinuation of methylphenidate in some patients. Clinical evaluation for anxiety, agitation or tension should precede use of methylphenidate and patients should be \*\*regularly monitored for the emergence or worsening of these symptoms during treatment, at every adjustment of dose and then at least every 6 months or every visit.\*\*
\*Forms of bipolar disorder\*
Particular care should be taken in using methylphenidate to treat ADHD in patients with comorbid bipolar disorder (including untreated Type I Bipolar Disorder or other forms of bipolar disorder) because of concern for possible precipitation of a mixed/manic episode in such patients. Prior to initiating treatment with methylphenidate, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. \*\*Close ongoing monitoring is essential in these patients (see above 'Psychiatric Disorders' and section 4.2). Patients should be monitored for symptoms at every adjustment of dose, then at least every 6 months and at every visit.\*\*
\*\*Growth\*\*
Moderately reduced weight gain and growth retardation have been reported with the long-term use of methylphenidate in children. Weight decrease has been reported with methylphenidate treatment in adults (see section 4.8).
The effects of methylphenidate on final height and final weight are currently unknown and being studied.
\*\*Growth should be monitored during methylphenidate treatment: height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart.\*\* Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted. In adults, weight should be regularly monitored.
\*\*Seizures\*\*
Methylphenidate should be used with caution in patients with epilepsy. Methylphenidate may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and rarely in patients without a history of convulsions and no EEG abnormalities. If seizure frequency increases or new- onset seizures occur, methylphenidate should be discontinued.
\*\*Abuse, misuse and diversion\*\*
Patients should be carefully monitored for the risk of diversion, misuse and abuse of methylphenidate. Methylphenidate should be used with caution in patients with known drug or alcohol dependency because of a potential for abuse, misuse or diversion.
Chronic abuse of methylphenidate can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially in response to parenteral abuse.
Patient age, the presence of risk factors for substance use disorder (such as co-morbid oppositional-defiant or conduct disorder and bipolar disorder), previous or current substance abuse should all be taken into account when deciding on a course of treatment for ADHD. Caution is called for in emotionally unstable patients, such as those with a history of drug or alcohol dependence, because such patients may increase the dosage on their own initiative.
For some high-risk substance abuse patients, methylphenidate or other stimulants may not be suitable and non- stimulant treatment should be considered.
\*\*Priapism.\*\*
Prolonged and painful erections have been reported in association with methylphenidate products, mainly in association with a change in the methylphenidate treatment regimen. Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.
\*\*Use with serotonergic medicinal products\*\*
Serotonin syndrome has been reported following co-administration of methylphenidate with serotonergic medicinal products. If concomitant use of methylphenidate with a serotonergic medicinal product is warranted, prompt recognition of the symptoms of serotonin syndrome is important. These symptoms may include mental-status changes (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g. hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea). Methylphenidate must be discontinued as soon as possible if serotonin syndrome is suspected.
\*\*Withdrawal\*\*
Careful supervision is required during methylphenidate withdrawal, since this may unmask depression as well as chronic over- activity. Some patients may require long-term follow up.
Careful supervision is required during withdrawal from abusive use since severe depression may occur.
\*\*Fatigue\*\*
Methylphenidate should not be used for the prevention or treatment of normal fatigue states.
\*\*Choice of methylphenidate formulation\*\*
The choice of formulation of methylphenidate-containing medicinal product will have to be decided by the treating specialist on an individual basis and depends on the intended duration of effect.
\*\*Drug screening\*\*
This medicinal product contains methylphenidate which may induce a false positive laboratory test for amphetamines, particularly with immunoassay screen test. Athletes must be aware that this medicinal product may cause a positive reaction to 'anti-doping' tests.
\*\*Renal or hepatic impairment\*\*
There is no experience with the use of methylphenidate in patients with renal or hepatic impairment.
\*\*Haematological effects\*\*
The long-term safety of treatment with methylphenidate is not fully known. In the event of leukopenia, thrombocytopenia, anaemia or other alterations, including those indicative of serious renal or hepatic disorders, discontinuation of treatment should be considered (see section 4.8).
\*\*Administration\*\*
Due to the prolonged-release design of the tablet, Xaggitin XL should only be used in patients who are able to swallow the tablet whole. Patients should be informed that Xaggitin XL must be swallowed whole with the aid of liquids. Tablets should not be chewed, broken, divided, or crushed.
\*\*Excipient\*\*
\*\*\*Lactose\*\*\*
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Pharmacokinetic interaction\*\*
It is not known how methylphenidate may effect plasma concentrations of concomitantly administered medicinal products. Therefore, caution is recommended at combining methylphenidate with other medicinal products, especially those with a narrow therapeutic window.
Methylphenidate is not metabolised by cytochrome P450 to a clinically relevant extent. Inducers or inhibitors of cytochrome P450 are not expected to have any relevant impact on methylphenidate pharmacokinetics. Conversely, the d- and l- enantiomers of methylphenidate do not relevantly inhibit cytochrome P450 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A.
However, there are reports indicating that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (e.g., phenobarbital, phenytoin, primidone), and some antidepressants (tricyclics and selective serotonin reuptake inhibitors). When starting or stopping treatment with methylphenidate, it may be necessary to adjust the dosage of these medicinal products already being taken and establish plasma concentrations (or for coumarin, coagulation times).
\*\*Pharmacodynamic interactions\*\*
\*Anti-hypertensive medicinal products\*
Methylphenidate may decrease the effectiveness of medicinal products used to treat hypertension.
\*Use with medicinal products that elevate blood pressure\*
Caution is advised in patients being treated with methylphenidate with any other medicinal product that can also elevate blood pressure (see also sections on cardiovascular and cerebrovascular conditions in section 4.4).
Because of possible hypertensive crisis, methylphenidate is contraindicated in patients being treated (currently or within the preceding 2 weeks) with non-selective, irreversible MAO-inhibitors (see section 4.3).
\*Use with alcohol\*
Alcohol may exacerbate the adverse CNS effect of psychoactive medicinal products, including methylphenidate. It is therefore advisable for patients to abstain from alcohol during treatment.
\*Use with serotonergic medicinal products\*
There have been reports of serotonin syndrome following co-administration of methylphenidate with serotonergic medicinal products. If concomitant use of methylphenidate with a serotonergic medicinal product is warranted, prompt recognition of the symptoms of serotonin syndrome is important (see section 4.4). Methylphenidate must be discontinued as soon as possible if serotonin syndrome is suspected.
\*Use with halogenated anaesthetics\*
There is a risk of sudden blood pressure and heart rate increase during surgery. If surgery is planned, methylphenidate treatment should not be used on the day of surgery.
\*Use with centrally acting alpha-2 agonists (e.g. clonidine)\*
Serious, adverse events, including sudden death, have been reported in concomitant use of methylphenidate and clonidine. The long-term safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systematically evaluated.
\*Use with dopaminergic medicinal products\*
Caution is recommended when administering methylphenidate with dopaminergic medicinal products, including antipsychotics. Because a predominant action of methylphenidate is to increase extracellular dopamine levels, methylphenidate may be associated with pharmacodynamic interactions when co-administered with direct and indirect dopamine agonists (including DOPA and tricyclic antidepressants) or with dopamine antagonists including antipsychotics.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Data from a cohort study of in total approximately 3,400 pregnancies exposed in the first trimester do not suggest an increased risk of overall birth defects. There was a small increased occurrence of cardiac malformations (pooled adjusted relative risk, 1.3; 95 % CI, 1.0-1.6) corresponding to 3 additional infants born with congenital cardiac malformations for every 1000 women who receive methylphenidate during the first trimester of pregnancy, compared with non-exposed pregnancies.
Cases of neonatal cardiorespiratory toxicity, specifically foetal tachycardia and respiratory distress have been reported in spontaneous case reports.
Studies in animals have shown evidence of reproductive toxicity at maternally toxic doses (see section 5.3). Methylphenidate is not recommended for use during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy
\*\*Breast-feeding\*\*
Methylphenidate is excreted in human milk. Based on reports of breast milk sampling from five mothers, methylphenidate concentrations in human milk resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage, and a milk to maternal plasma ratio ranging between 1.1 and 2.7.
There is one case report of an infant who experienced an unspecified decrease in weight during the period of exposure but recovered and gained weight after the mother discontinued treatment with methylphenidate. A risk to the suckling child cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from methylphenidate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
\*\*Fertility\*\*
No human data on the effect of methylphenidate on fertility are available. There were no relevant effects observed in the non-clinical studies.4.7 Effects on ability to drive and use machines
Methylphenidate can cause dizziness, drowsiness and visual disturbances including difficulties with accommodation, diplopia and blurred vision. It may have a moderate influence on the ability to drive and use machines. Patients should be warned of these possible effects and advised that if affected, they should avoid potentially hazardous activities such as driving or operating machinery.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
| | |
| --- | --- |
| | - The medicine has been prescribed to treat a medical or dental problem and - You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and - It was not affecting your ability to drive safely. |4.8 Undesirable effects
The table below shows all adverse reactions observed during clinical trials of children, adolescents, and adults and post-market spontaneous reports with methylphenidate prolonged-release tablets and those, which have been reported with other methylphenidate hydrochloride formulations. If the adverse with methylphenidate prolonged-release tablets and the methylphenidate formulation frequencies were different, the highest frequency of both databases was used.
Frequency estimate:
Very common (≥ 1/10)
Common (≥ 1/100 to < 1/10)
Uncommon (≥ 1/1,000 to < 1/100)
Rare (≥ 1/10,000 to < 1/1,000)
Very rare (< 1/10,000)
Not known (cannot be estimated from the available data).
| | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| System Organ Class | Adverse Reaction | | | | | |
| Frequency | | | | | |
| Very Common | Common | Uncommon | Rare | Very rare | Not known |
| Infections and infestations | | Nasopharyngitis, Upper respiratory tract infection#, Sinusitis# | | | | |
| Blood and lymphatic system disorders | | | | | Anaemia†, Leucopenia†, Thrombocytopenia, Thrombocytopenic purpura | Pancytopenia |
| Immune system disorders | | | Hypersensitivity reactions such as Angioneurotic oedema, Anaphylactic reactions, Auricular swelling, Bullous conditions, Exfoliative conditions, Urticarias, Pruritus, Rashes, and Eruptions | | | |
| Metabolism and nutrition disorders\\* | | Anorexia, Decreased appetite†, Moderately reduced weight and height gain during prolonged use in children\\* | | | | |
| Psychiatric disorders\\* | Insomnia, Nervousness | Affect lability, Aggression\\*, Agitation\\*, Anxiety\\*†, Depression\\*, #, Irritability, Abnormal behaviour, Mood swings, Tics\\*, Initial insomnia#, Depressed mood#, Libido decreased#, Tension#, Bruxism#, ‡, Panic attack# | Psychotic disorders\\*, Auditory, visual and tactile hallucination\\*, Anger, Suicidal ideation\\*, Mood altered, Restlessness†, Tearfulness, Worsening of pre-existing tics of Tourette's syndrome\\*, Logorrhoea, Hypervigilance, Sleep disorder | Mania\\*†, Disorientation, Libido disorder, Confusional state† | Suicidal attempt (including completed suicide) \\* †, Transient depressed mood\\*, Abnormal thinking, Apathy†, Repetitive behaviours, Over- focussing | Delusions\\*†, Thought disturbances\\*, Dependence. Cases of abuse and dependence have been described, more often with immediate release formulations |
| Nervous system disorders | Headache | Dizziness, Dyskinesia, Psychomotor hyperactivity, Somnolence, Paresthaesia#, Tension headache# | Sedation, Tremor†, Lethargy# | | Convulsion, Choreo-athetoid movements, Reversible ischaemic neurological deficit, Neuroleptic malignant syndrome (NMS; Reports were poorly documented and in most cases, patients were also receiving other medicinal products, so the role of methylphenidate is unclear). | Cerebrovascular disorders\\*† (including vasculitis, cerebral haemorrhages, cerebrovascular accidents, cerebral arteritis, cerebral occlusion), Grand mal convulsion\\*, Migraine†, Dysphemia |
| Eye disorders | | Accommodation disorder# | Blurred vision†, Dry eye# | Difficulties in visual accommodation, Visual impairment, Diplopia | | Mydriasis |
| Ear and labyrinth disorders | | Vertigo# | | | | |
| Cardiac disorders\\* | | Arrhythmia, Tachycardia, Palpitations | Chest pain | Angina pectoris | Cardiac arrest, Myocardial infarction | Supraventricular tachycardia, Bradycardia, Ventricular extrasystoles†, Extrasystoles† |
| Vascular disorders\\* | | Hypertension | Hot flush# | | Cerebral arteritis and/or occlusion, Peripheral coldness†, Raynaud's phenomenon | |
| Respiratory, thoracic and mediastinal disorders | | Cough, Oropharyngeal pain | Dyspnoea† | | | Epistaxis |
| Gastrointestinal disorders | | Abdominal pain upper, Diarrhoea, Nausea†, Abdominal discomfort, Vomiting, Dry mouth†, Dyspepsia# | Constipation† | | | |
| Hepatobiliary disorders | | Alanine aminotransferase increased# | Hepatic enzyme elevations | | Abnormal liver function, including Acute hepatic failure and hepatic coma, Blood alkaline phosphatase increased, Blood bilirubin increased† | |
| Skin and subcutaneous tissue disorders | | Alopecia, Hyperhidrosis†, Pruritis, Rash, Urticaria | Angioneurotic oedema, Bullous conditions, Exfoliative conditions | Macular rash; Erythema | Erythema multiforme, Exfoliative dermatitis, Fixed drug eruption | |
| Musculoskeletal and connective tissue disorders | | Arthralgia, Muscle tightness#, Muscle spasms# | Myalgia†, Muscle twitching | | Muscle cramps | Trismus‡ |
| Renal and urinary disorders | | | Haematuria, Pollakiuria | | | Incontinence |
| Reproductive system and breast disorders | | Erectile dysfunction# | | Gynaecomastia | | Priapism\\*, Erection increased\\* and Prolonged erection\\* |
| General disorders and administration site conditions | | Pyrexia, Growth retardation during prolonged use in children\\*, Fatigue†, Irritability#, Feeling jittery#, Asthenia#, Thirst# | Chest pain | | Sudden cardiac death\\* | Chest discomfort†, Hyperpyrexia |
| Investigations | | Changes in blood pressure and heart rate (usually an increase)\\*, Weight decreased\\*, Alanine aminotransferase increased# | Cardiac murmur\\* | | Platelet count decreased, White blood cell count abnormal | |
\\* See section 4.4
# Frequency derived from adult clinical trials and not on data from trials in children and adolescents; may also be relevant for children and adolescents.
† Adverse drug reaction from clinical trials in adult patients that were and reported with a higher frequency than in children and adolescents.
‡ Based on the frequency calculated in adult ADHD studies (no cases were reported in the paediatric studies).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
When treating patients with overdose, allowances must be made for the delayed release of methylphenidate from formulations with extended durations of action.
\*\*Signs and Symptoms\*\*
Acute overdose, mainly due to overstimulation of the central and sympathetic nervous systems, may result in vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, dryness of mucous membranes and rhabdomyolysis.
\*\*Treatment\*\*
There is no specific antidote to methylphenidate overdosage. Treatment consists of appropriate supportive measures.
The patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. The efficacy of activated charcoal has not been established.
Intensive care must be provided to maintain adequate circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia.
Efficacy of peritoneal dialysis or extracorporeal haemodialysis for overdose of methylphenidate has not been established.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: centrally acting sympathomimetics: ATC code: N06BA04
\*\*Mechanism of action\*\*
Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space. Methylphenidate is a racemic mixture comprised of the d- and l-isomers. The d-isomer is more pharmacologically active than the l-isomer.
\*\*Clinical efficacy and safety\*\*
\*\*\*Children\*\*\*
In the pivotal clinical studies, methylphenidate prolonged-release tablets were assessed in 321 paediatric patients already stabilised with immediate release preparations (IR) of methylphenidate and in 95 paediatric patients not previously treated with IR preparations of methylphenidate.
Clinical studies in paediatric patients showed that the effects of methylphenidate prolonged-release tablets were maintained until 12 hours after dosing when the product was taken once daily in the morning.
\*Adults\*
Short-term efficacy has been demonstrated for methylphenidate prolonged-release tablets in a dosage range of 18 to 72 mg/day. One thousand five hundred and twenty-three (1523) adults with ADHD aged 18 to 65 years were evaluated in five double-blind, placebo-controlled studies of 5 to 13 weeks duration. Methylphenidate prolonged-release tablets were evaluated in 2 fixed-dose studies and 3 flexible dose studies, using DSM-IV based instruments for the assessment of ADHD symptom severity in adults. In two fixed-dose studies, Conner's Adult ADHD Rating Scales (CAARS) showed that total scores of ADHD symptoms decreased, indicating an improvement in the severity of ADHD symptoms, from baseline to double-blind end point. In one fixed-dose study, all dose levels of methylphenidate prolonged-release tablets showed clinically significantly greater symptom control (p<0.05 for all dose levels), compared to placebo as measured by a reduction in CAARS total score. In the second fixed-dose study, methylphenidate prolonged-release tablets 72 mg/day but not methylphenidate prolonged-release tablets 54 mg/day, proved to be statistically significant over placebo in reducing the CAARS ADHD symptoms total score from baseline to double-blind end point among adult subjects with ADHD (p-value 0.0024).
In two flexible dose studies, the LS mean changes from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score at endpoint were statistically significant (Study 1: p = 0.012; Study 2: p<0.001) for final methylphenidate prolonged-release tablets dose treatment over placebo (Study 1: -10.6 for methylphenidate prolonged-release tablets vs -6.8 placebo; Study 2: -16.9 for methylphenidate prolonged-release tablets vs -12.0 for placebo). In the third flexible dose study (Study 3), methylphenidate prolonged-release tablets showed clinically significantly greater symptom control (p<0.0001) compared to placebo as measured by a reduction in CAARS total score. The LS mean change from baseline to Final Visit (Week 8) in the total ADHD Symptoms Scores of CAARS-O:SV was -10.9 in the methylphenidate prolonged-release tablets group and -6.9 in the placebo group (based on the ITT population).
In flexible dose Study 2, the magnitude of improvement in the total AISRS scores was statistically significantly larger in the methylphenidate prolonged-release tablets group than in the placebo group (p = 0.0037). The LS mean (95% CI) difference from placebo was -5.3 (-8.9, -1.7). In flexible dose Study 3, the magnitude of improvement in the CAARS-O:SV scores was statistically significantly larger in the methylphenidate prolonged-release tablets group than in the placebo group (p = 0.0063). The LS mean (95% CI) difference from placebo was -3.9 (-6.6, -1.1).
Adults treated with methylphenidate prolonged-release tablets in four long-term open-label studies over 6 to 12 months showed improvement in all efficacy endpoints evaluated, indicating stable effects over time on the reduction in ADHD symptoms. In one open-label study in a community setting, methylphenidate prolonged-release tablets treatment for up to 9 months showed improvement from baseline values in mean global assessment of efficacy scores by both the patient and the investigator. In a second study, in which adults with ADHD received methylphenidate prolonged-release tablets for up to 1 year with a mean final dose of 67.4 mg/day showed clinically meaningful improvements from baseline in AISRS total scores with a mean change of -18.7 at the final visit. In a third long-term study of 48 weeks, adults with ADHD received methylphenidate prolonged-release tablets with a mean final dose of 46.6 mg/day showed a change from baseline in the mean DSM-IV Total ADHD symptoms score of CAARS by -17.2 at endpoint. In the fourth study, methylphenidate prolonged-release tablets were evaluated in a 52-week open label study in subjects who had previously completed a short-term placebo-controlled trial and short-term open-label extension. Adults with ADHD received methylphenidate prolonged-release tablets with a mean final dose of 53.8 mg/day showed stable effects over time on reductions in ADHD symptoms. Investigator-rated CAARS improved throughout the open-label phase and was lower at endpoint (mean decrease by 1.9 from baseline).5.2 Pharmacokinetic properties
\*\*Absorption\*\*
Methylphenidate is readily absorbed. Following oral administration of methylphenidate prolonged-release tablets to adults the tablet coating dissolves, providing an initial maximum methylphenidate concentration at about 1 to 2 hours. The methylphenidate contained in the tablet core is gradually released over the next several hours. Peak plasma concentrations are achieved at about 6 to 8 hours, after which plasma levels of methylphenidate gradually decrease. Methylphenidate prolonged-release tablets taken once daily minimises the fluctuations between peak and trough concentrations associated with immediate-release methylphenidate three times daily. The extent of absorption of methylphenidate prolonged-release tablets once daily is generally comparable to conventional immediate release preparations.
Following the administration of methylphenidate prolonged-release tablets 18 mg once daily in 36 adults, the mean pharmacokinetic parameters were: Cmax 3.7 ± 1.0 (ng/mL), tmax 6.8 ± 1.8 (h), AUCinf 41.8 ± 13.9 (ng.h/mL), and t½ 3.5 ± 0.4 (h).
No differences in the pharmacokinetics of methylphenidate prolonged-release tablets were noted following single and repeated once daily dosing, indicating no significant methylphenidate accumulation. The AUC and t½ following repeated once daily dosing are similar to those following the first dose of methylphenidate prolonged-release tablets 18 mg.
Following administration of methylphenidate prolonged-release tablets in single doses of 18 to 72 mg/day to adults, Cmax and AUCinf of methylphenidate were proportional to dose.
\*\*Distribution\*\*
Plasma methylphenidate concentrations in adults decline biexponentially following oral administration. The half-life of methylphenidate in adults following oral administration of methylphenidate prolonged-release tablets was approximately 3.5 h. The rate of protein binding of methylphenidate and of its metabolites is approximately 15%. The apparent volume of distribution of methylphenidate is approximately 13 litres/kg.
\*\*Biotransformation\*\*
In humans, methylphenidate is metabolised primarily by de-esterification to alpha-phenyl-piperidine acetic acid (PPA, approximately 50 fold the level of the unchanged substance) which has little or no pharmacologic activity. In adults the metabolism of methylphenidate prolonged-release tablets once daily as evaluated by metabolism to PPA is similar to that of methylphenidate three times daily. The metabolism of single and repeated once daily doses of methylphenidate prolonged-release tablets is similar.
\*\*Elimination\*\*
The elimination half-life of methylphenidate in adults following administration of methylphenidate prolonged-release tablets was approximately 3.5 hours. After oral administration, about 90% of the dose is excreted in urine and 1 to 3% in faeces, as metabolites within 48 to 96 hours. Small quantities of unchanged methylphenidate are recovered in urine (less than 1%). The main urinary metabolite is alpha-phenyl-piperidine acetic acid (60-90%).
After oral dosing of radiolabelled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was PPA, accounting for approximately 80% of the dose.
\*\*Food effects\*\*
In patients, there were no differences in either the pharmacokinetics or the pharmacodynamic performance of methylphenidate prolonged-release tablets when administered after a high fat breakfast on an empty stomach.
\*\*Special populations\*\*
\*Gender\*
In healthy adults, the mean dose-adjusted AUCinf values for methylphenidate prolonged-release tablets were 36.7 ng.h/mL in men and 37.1 ng.h/mL in women, with no differences noted between the two groups.
\*Race\*
In healthy adults receiving methylphenidate prolonged-release tablets, dose-adjusted AUCinf was consistent across ethnic groups; however, the sample size may have been insufficient to detect ethnic variations in pharmacokinetics.
\*Age\*
The pharmacokinetics of methylphenidate prolonged-release tablets has not been studied in children younger than 6 years of age. In children 7-12 years of age, the pharmacokinetics of methylphenidate prolonged-release tablets after 18, 36 and 54 mg were (mean±SD): Cmax 6.0 ± 1.3, 11.3 ± 2.6, and 15.0 ± 3.8 ng/mL, respectively, tmax 9.4 ± 0.02, 8.1 ± 1.1, 9.1 ± 2.5 h, respectively, and AUC0-11.5 50.4 ± 7.8, 87.7 ± 18.2, 121.5 ± 37.3 ng.h/mL, respectively.
\*Renal impairment\*
There is no experience with the use of methylphenidate prolonged-release tablets in patients with renal impairment. After oral administration of radiolabelled methylphenidate in humans, methylphenidate was extensively metabolised and approximately 80% of the radioactivity was excreted in the urine in the form of PPA. Since renal clearance is not an important route of methylphenidate clearance, renal impairment is expected to have little effect on the pharmacokinetics of methylphenidate prolonged-release tablets.
\*Hepatic impairment\*
There is no experience with the use of methylphenidate prolonged-release tablets in patients with hepatic impairment.5.3 Preclinical safety data
\*\*Carcinogenicity\*\*
In life-time rat and mouse carcinogenicity studies, increased numbers of malignant liver tumours were noted in male mice only. The significance of this finding to humans is unknown.
Methylphenidate did not affect reproductive performance or fertility at low multiples of the clinical dose.
\*\*Pregnancy-embryonal/foetal development\*\*
Methylphenidate is not considered to be teratogenic in rats and rabbits. Foetal toxicity (i.e. total litter loss) and maternal toxicity was noted in rats at maternally toxic doses.
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Tablet core\*\*
Lactose monohydrate
Hypromellose
Silica, colloidal anhydrous
Magnesium stearate
Fumaric acid
Methacrylic acid–methyl methacrylate copolymer
Triethyl citrate
Talc
\*\*Tablet coating\*\*
\*18 mg prolonged-release tablets:\*
Polyvinyl alcohol, part hydrolyzed
Macrogol (3350)
Talc
Titanium dioxide (E171)
Iron oxide yellow (E172)
Iron oxide red (E172)
\*27 mg prolonged-release tablets:\*
Polyvinyl alcohol, part hydrolyzed
Macrogol (3350)
Talc
Titanium dioxide (E171)
Iron oxide yellow (E172)
Indigo carmine aluminium lake (E132)
Iron oxide black (E172)
\*36 mg prolonged-release tablets:\*
Polyvinyl alcohol, part hydrolyzed
Macrogol (3350)
Talc
Titanium dioxide (E171)
\*54 mg prolonged-release tablets:\*
Polyvinyl alcohol, part hydrolyzed
Macrogol (3350)
Talc
Titanium dioxide (E171)
Iron oxide red (E172)
\*\*Printing ink\*\*
Shellac glaze
Iron oxide black (E172)
Propylene glycol6.2 Incompatibilities
Not applicable.6.3 Shelf life
2 years
Shelf life after first opening the bottle:
18 mg tablets: 3 months
27 mg tablets: 6 months
36 mg tablets: 6 months
54 mg tablets: 6 months6.4 Special precautions for storage
This medicinal product does not require any special storage conditions6.5 Nature and contents of container
HDPE bottle with a child-resistant PP closure with silica gel desiccant integrated into the closure.
18 mg tablets: 28, 29, 30 or 90 prolonged-release tablets.
27 mg tablets: 28, 29, 30 or 100 prolonged-release tablets.
36 mg tablets: 28, 29, 30 or 100 prolonged-release tablets.
54 mg tablets: 28, 29, 30 or 100 prolonged-release tablets.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
No special requirements
